Decheng Capital Management III (Cayman), LLC has filed an updated Schedule 13G/A with the SEC, revealing a significant stake in BeyondSpring Inc. The filing, dated October 29, 2026, indicates that Decheng now holds 1,448,293 ordinary shares of BeyondSpring, representing 3.5% of the company's total shares outstanding. This development is noteworthy as it highlights Decheng's ongoing commitment to investing in the pharmaceutical sector.

Background

Decheng Capital Management III is a Cayman Islands-based investment firm focused on the life sciences sector. The firm has been active in the market, with its recent filings showing a strategic approach to investments in pharmaceutical companies. BeyondSpring Inc., the subject of this filing, operates within the pharmaceutical preparations industry, specifically focusing on developing innovative cancer therapies.

What the Filing Says

The filing confirms that Decheng Capital Management III beneficially owns 1,448,293 ordinary shares of BeyondSpring as of September 30, 2026. The filing states, "The Reporting Persons' ownership of the Issuer's securities consists of (i) 1,448,293 ordinary shares held directly by Fund III and (ii) 1,617,409 ordinary shares held directly by Fund II." This indicates a structured investment strategy involving multiple funds managed by Decheng.

Impact

This increase in ownership may affect various stakeholders, including BeyondSpring's management and other investors. Decheng's significant stake could provide it with a voice in corporate governance and strategic decisions at BeyondSpring, potentially influencing the company's future direction in the competitive pharmaceutical market.

What's Next

The filing does not say what happens next.